Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Campion

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Nucleic Acid Therapeutics|August 20, 2014
Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeuticsJoy Cavagnaro, Cindy Berman, Doug Kornbrust, et al.
Archives of Toxicology|February 16, 2023
Circulating microRNAs as promising testicular translatable safety biomarkers: current state and future perspectivesJiangwei Zhang, Sarah Campion, Natasha Catlin, et al.
Experientia Supplementum (2012)|September 5, 2012
Male reprotoxicity and endocrine disruptionSarah Campion, Natasha Catlin, Nicholas Heger, et al.
Cytotherapy|July 30, 2024
Automation preserves product consistency and quality for the formulation, fill, and finish of T cell-based therapiesMinsung Park, Meredith Safford, Jade Scheers, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 22, 2013
The current status of biomarkers for predicting toxicitySarah Campion, Jiri Aubrecht, Kim Boekelheide, et al.
Disease Models & Mechanisms|April 25, 2022
The benefits, limitations and opportunities of preclinical models for neonatal drug developmentSarah Campion, Amy Inselman, Belinda Hayes, et al.
ALTEX|July 18, 2013
In vitro testicular toxicity models: opportunities for advancement via biomedical engineering techniquesLouise Parks Saldutti, Bruce K Beyer, William Breslin, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Nucleic Acid Therapeutics|August 20, 2014
Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeuticsJoy Cavagnaro, Cindy Berman, Doug Kornbrust, et al.
Archives of Toxicology|February 16, 2023
Circulating microRNAs as promising testicular translatable safety biomarkers: current state and future perspectivesJiangwei Zhang, Sarah Campion, Natasha Catlin, et al.
Experientia Supplementum (2012)|September 5, 2012
Male reprotoxicity and endocrine disruptionSarah Campion, Natasha Catlin, Nicholas Heger, et al.
Cytotherapy|July 30, 2024
Automation preserves product consistency and quality for the formulation, fill, and finish of T cell-based therapiesMinsung Park, Meredith Safford, Jade Scheers, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 22, 2013
The current status of biomarkers for predicting toxicitySarah Campion, Jiri Aubrecht, Kim Boekelheide, et al.
Disease Models & Mechanisms|April 25, 2022
The benefits, limitations and opportunities of preclinical models for neonatal drug developmentSarah Campion, Amy Inselman, Belinda Hayes, et al.
ALTEX|July 18, 2013
In vitro testicular toxicity models: opportunities for advancement via biomedical engineering techniquesLouise Parks Saldutti, Bruce K Beyer, William Breslin, et al.
Pageof 1